Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Source ↗
👁 0
💬 0
The post Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up appeared first on 24/7 Wall St..
Moderna (NASDAQ:MRNA) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine maker inside one of the most widely tracked growth benchmarks in the market.
Meanwhile, Pfizer (NYSE:PFE) stock is at $28.02, up 0.7%, a far smaller gain than the one in Moderna stock. Additionally, BioNTech (NASD
Moderna (NASDAQ:MRNA) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine maker inside one of the most widely tracked growth benchmarks in the market.
Meanwhile, Pfizer (NYSE:PFE) stock is at $28.02, up 0.7%, a far smaller gain than the one in Moderna stock. Additionally, BioNTech (NASD
Comments (0)